DOW JONES27,960.80-1031.61 -3.56%
S&P 5003,225.89-111.86 -3.35%
NASDAQ9,221.28-355.31 -3.71%

Mizuho Initiates Coverage On Neurocrine Biosciences with Neutral Rating, Announces $107 Price Target

Mizuho analyst Vamil Divan initiates coverage on Neurocrine Biosciences (NASDAQ:NBIX) with a Neutral rating and a $107 price target.

Benzinga · 02/06/2020 10:14

Mizuho analyst Vamil Divan initiates coverage on Neurocrine Biosciences (NASDAQ:NBIX) with a Neutral rating and a $107 price target.